Open AccessIn vitro activity of LY127935
Author(s) -
Michael Barza,
Francis P. Tally,
Nilda V. Jacobus,
Sherwood L. Gorbach
Publication year - 1979
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.16.3.287
Subject(s) - bacteroides fragilis , microbiology and biotechnology , cefoxitin , piperacillin , tobramycin , serratia marcescens , klebsiella pneumoniae , pseudomonas aeruginosa , enterobacter , staphylococcus aureus , biology , cefotaxime , carbenicillin , cefamandole , amikacin , antibiotics , proteus mirabilis , escherichia coli , cephalosporin , gentamicin , bacteria , biochemistry , genetics , gene
The activity of LY127935, a beta-lactam antibiotic of novel structure, was studied in vitro against facultative gram-negative bacilli, Staphylococcus aureus, and Bacteroides fragilis. The strains were recent clinical isolates, many of which were relatively resistant to other antibiotics. LY127935 exhibited striking activity against Escherichia coli, Klebsiella pneumoniae, Enterobacter sp., Proteus sp., Serratia marcescens, and B. fragilis with median minimum inhibitory concentrations of less than or equal to 1.0 micrograms/ml. It was somewhat less active against Pseudomonas aeruginosa and S. aureus. Cefotaxime (HR 756) showed very similar activity except that it was substantially weaker against B. fragilis. LY127935 was more active than cefamandole, cefoxitin, or piperacillin; it was also as potent as tobramycin or amikacin against all species except for P. aeruginosa.